However, to the best of our knowledge, we are the first to demonstrate that PAR2 blockade impairs C-PAF-induced neutrophil adhesion and rolling, CXCL1 and CXCL2 lung production, suggesting that PAR2 blockade may be useful in inflammatory diseases where PAF plays a central role on the development and progression of the inflammatory disease through the impairment of early events of lung diseases, such as neutrophil migration. The gene discussed is PCLAF; the disease is lung disorder.